Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
Podcasts
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
Podcasts
About
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
DAS28, 28 joint disease activity score
Email alerts
DAS28, 28 joint disease activity score
Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register
K
Hyrich
,
D
Symmons
,
K
Watson
,
A
Silman
,
BSRBR Control Centre Consortium
Annals of the Rheumatic Diseases
Jul 2006,
65
(7)
895-898;
DOI:
10.1136/ard.2005.043158
Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice
A A
den Broeder
,
E
de Jong
,
M J A M
Franssen
,
M E C
Jeurissen
,
M
Flendrie
,
F H J
van den Hoogen
Annals of the Rheumatic Diseases
Jun 2006,
65
(6)
760-762;
DOI:
10.1136/ard.2004.033662
Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab
A
Kuuliala
,
R
Nissinen
,
H
Kautiainen
,
H
Repo
,
M
Leirisalo-Repo
Annals of the Rheumatic Diseases
Jan 2006,
65
(1)
26-29;
DOI:
10.1136/ard.2004.034728
Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis
A
Häkkinen
,
H
Kautiainen
,
P
Hannonen
,
J
Ylinen
,
H
Mäkinen
,
T
Sokka
Annals of the Rheumatic Diseases
Jan 2006,
65
(1)
30-34;
DOI:
10.1136/ard.2004.034769
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis
H A
Chen
,
K C
Lin
,
C H
Chen
,
H T
Liao
,
H P
Wang
,
H N
Chang
,
C Y
Tsai
,
C T
Chou
Annals of the Rheumatic Diseases
Jan 2006,
65
(1)
35-39;
DOI:
10.1136/ard.2005.038851
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis
M M J
Nielen
,
A R
van der Horst
,
D
van Schaardenburg
,
I E
van der Horst-Bruinsma
,
R J
van de Stadt
,
L
Aarden
,
B A C
Dijkmans
,
D
Hamann
Annals of the Rheumatic Diseases
Aug 2005,
64
(8)
1199-1204;
DOI:
10.1136/ard.2004.029389
Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12
M
van Oosterhout
,
E W N
Levarht
,
J K
Sont
,
T W J
Huizinga
,
R E M
Toes
,
J M
van Laar
Annals of the Rheumatic Diseases
Apr 2005,
64
(4)
537-543;
DOI:
10.1136/ard.2004.024927
Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis
J
Wolf
,
T
Stranzl
,
M
Filipits
,
G
Pohl
,
R
Pirker
,
B
Leeb
,
J S
Smolen
Annals of the Rheumatic Diseases
Apr 2005,
64
(4)
564-568;
DOI:
10.1136/ard.2003.014985
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
E N
van Roon
,
T L T A
Jansen
,
M A F J
van de Laar
,
M
Janssen
,
J P
Yska
,
R
Keuper
,
P M
Houtman
,
J R B J
Brouwers
Annals of the Rheumatic Diseases
Apr 2005,
64
(4)
569-574;
DOI:
10.1136/ard.2004.025205
Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists
J
Sany
,
P
Bourgeois
,
A
Saraux
,
S
Durieux
,
A
Lafuma
,
J P
Daurès
,
F
Guillemin
,
J
Sibilia
Annals of the Rheumatic Diseases
Oct 2004,
63
(10)
1235-1240;
DOI:
10.1136/ard.2003.013110
Pages
1
2
next ›
last »
CLINICAL
Diagnostics
Clinical diagnostic tests
(1563)
Radiology (diagnostics)
(921)
Surgical diagnostic tests
(505)
Drugs and medicines
Endocrinology
Calcium and bone
(938)
Evidence based practice
Guidelines
(35)
Gastroenterology
Inflammatory bowel disease
(98)
Genetics
(1272)
Immunology (including allergy)
(6648)
Infectious diseases
Bone and joint infections
(93)
Travel medicine
(42)
Neurology
Muscle disease
(198)
Pain (neurology)
(1113)
Nutrition and metabolism
Obesity (nutrition)
(142)
Obstetrics and gynaecology
Menopause (including HRT)
(60)
Ophthalmology
(155)
Orthopaedics
Pathology
Inflammation
(1572)
Pathology
(531)
Pharmacology and therapeutics
Unwanted effects / adverse reactions
(15)
Pharmacology and therapeutics
Radiology
(1357)
Rehabilitation medicine
Disability
(32)
Other rehabilitative therapies
(18)
Physiotherapy
(52)
Renal medicine
(247)
Respiratory medicine
Interstitial lung disease
(181)
Pulmonary hypertension
(39)
Rheumatology
Ankylosing spondylitis
(567)
Biological agents
(731)
Connective tissue disease
(5506)
Degenerative joint disease
(6038)
Drugs: musculoskeletal and joint diseases
(916)
Fibromyalgia
(51)
Musculoskeletal syndromes
(6412)
Osteoarthritis
(1189)
Osteoporosis
(160)
Rheumatoid arthritis
(4213)
Sjogren's syndrome
(6)
Systemic lupus erythematosus
(724)
Vascularitis
(367)
Sports and exercise medicine
Physiotherapy
(33)
NON-CLINICAL
Epidemiology
(1862)
Health economics
(51)
Medical education
Postgraduate
(5)
Occupational and environmental medicine
(32)
Statistics and research methods
Special collections
ARD Lay summaries
(83)
Editor's choice
(161)
Guidelines, Recommendations and Consensus Statements
Open access
(1199)
Press releases
(50)